Lupus: Open Access
Open Access

Importance of Antinuclear Antibodies (ANA) in Lupus Treatment

Kevin Miller^{* *}Correspondence: Kevin Miller, Department of Applied Science, University of Bonn, Bonn, Germany, Email:

Author info »

Description

Antinuclear Antibodies (ANA) are a group of antibodies that target the cell's nucleus, specifically the proteins and structures inside the nucleus. These antibodies are commonly associated with autoimmune diseases, most notably Systemic Lupus Erythematosus (SLE), a chronic inflammatory disorder that primarily affects the skin, joints, kidneys, and other organs. ANA testing is a crucial diagnostic tool for lupus, as the presence of these antibodies is found in a significant proportion of individuals with the disease. However, ANA can also be found in other autoimmune diseases and even in healthy individuals, making the interpretation of ANA tests complex and requiring clinical correlation [1].

In lupus, the immune system erroneously attacks the body’s own tissues and organs. This misdirected immune response leads to inflammation, tissue damage, and the production of various antibodies, including ANA. ANA in lupus patients target the nuclear components of cells, such as DNA, histones, and ribonucleoproteins, leading to the formation of immune complexes that can deposit in tissues, contributing to inflammation and damage. These deposits can cause harm to various organs, especially the kidneys, joints, and skin, all common sites of involvement in lupus [2].

ANA are not specific to lupus; they can be present in other autoimmune diseases such as rheumatoid arthritis, scleroderma, and Sjogren’s syndrome. However, their presence in high titers (concentration levels) is strongly suggestive of lupus, especially when accompanied by clinical signs such as a butterfly-shaped rash on the face, photosensitivity, and joint pain. The detection of ANA is an essential component in the diagnosis of lupus. The most commonly used test to detect ANA is the indirect Immunofluorescence Assay (IFA), which involves incubating a patient’s serum with cells, typically from an animal or human, and then observing the fluorescent pattern formed by binding of antibodies [3]. The presence of ANA can be detected by the pattern of fluorescence observed under a microscope. The result of an ANA test is often reported as a titer, which is the highest dilution of the serum that still produces a positive result. A higher titer generally indicates a more significant presence of ANA. In lupus, a titer of 1:160 or higher is commonly observed, although lower titers can also be seen in individuals with the disease [4].

There are several distinct patterns of ANA staining that may be observed, and these patterns can provide clues about the type of autoimmune disease present. For example, a homogeneous pattern, which shows a uniform staining of the nucleus, is commonly associated with SLE, whereas a speckled pattern is often found in a variety of autoimmune conditions, including lupus [5]. It is important to note that ANA testing alone is not sufficient to diagnose lupus. A positive ANA result should be followed by further clinical evaluation, as ANA can be present in a variety of other conditions, including infections, cancers, and even in healthy individuals, particularly older adults [6].

The presence of ANA in lupus patients is a hallmark of the disease, but it is not always indicative of disease activity. ANA levels may remain positive even during periods of remission or when symptoms are not present. In fact, a significant proportion of individuals with lupus may have high ANA titers but remain asymptomatic. Conversely, some individuals with lupus may not have detectable ANA, making the diagnosis more challenging [7].

Despite these nuances, ANA testing remains an essential part of the lupus diagnostic process. A positive ANA test result, in combination with other clinical findings such as photosensitive rashes, oral ulcers, and joint inflammation, can aid in confirming a diagnosis of lupus. The pattern of ANA and the levels of specific subtypes of ANA can also offer insights into the potential severity and organ involvement in lupus. For instance, antibodies against double-stranded DNA (anti-dsDNA) are highly specific to lupus and are associated with more severe forms of the disease, especially kidney involvement. Other autoantibodies, such as anti-Smith (anti-Sm), are also highly specific to lupus and are seen in a subset of patients. The detection of these specific antibodies can help differentiate lupus from other autoimmune diseases with similar presentations [8].

While ANA testing plays a critical role in the diagnosis of lupus, its utility in monitoring disease progression and treatment response is less clear. In some cases, ANA titers may correlate with disease flares or worsening of symptoms, but this is not always the case. Some patients may experience a flare of lupus despite a low or stable ANA titer, while others may show improvements in ANA levels despite ongoing disease activity. ANA titers may fluctuate over time, and changes in titer levels can sometimes provide clues about disease activity or remission. However, other biomarkers, such as anti-dsDNA, complement levels, and clinical assessments, are typically more reliable indicators of disease activity and organ involvement. Therefore, ANA testing is primarily used as a diagnostic tool rather than a routine monitoring test in established lupus cases [9].

ANA are a critical component of the diagnostic process for SLE. While ANA testing is not specific to lupus and can be found in other autoimmune diseases and even in healthy individuals, a positive result, especially when accompanied by characteristic clinical symptoms, can help establish the diagnosis. The interpretation of ANA results should always be done in conjunction with the patient’s clinical presentation, as ANA levels alone cannot confirm or rule out lupus. In lupus patients, the presence of specific ANA subtypes, such as anti-dsDNA and anti-Smith antibodies, can provide valuable information regarding disease activity and potential organ involvement. Although ANA testing is not typically used to monitor disease progression, it remains an indispensable tool in the initial diagnosis of lupus and can assist in distinguishing it from other autoimmune conditions. Understanding the complexities of ANA testing and its relationship to lupus is essential for clinicians in providing accurate diagnoses and effective management of this challenging and multifaceted disease [10].

References

1. Bindu S, Dandapat S, Manikandan R, Dinesh M, Subbaiyan A, Mani P et al. Prophylactic and therapeutic insights into trained immunity: A renewed concept of innate immune memory. Hum Vaccines Immunother. 2022;18(1):2040238.

   [Crossref] [Google Scholar] [PubMed]

2. Modica RF, Thatayatikom A, Bell-Brunson DH, Elder ME. Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: A case series and mini-review of B-cell immunomodulation in antibody-mediated diseases. Clin Rheumatol.  2023;42(7):1965-1979.

   [Google Scholar]

3. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-3930.

   [Crossref] [Google Scholar] [PubMed]

4. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenz RE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731.

   [Crossref] [Google Scholar] [PubMed]

5. Marinho A, Delgado Alves J, Fortuna J, Faria R, Almeida I, Alves G et al. Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren’s syndrome: Evidence and practice-based guidance. Front Immunol. 2023;14:1117699.

   [Crossref] [Google Scholar] [PubMed]

6. Krustev E, Clarke AE, Barber MRW. B cell depletion and inhibition in systemic lupus erythematosus. Expert Rev Clin Immunol. 2023;19(1):55-70.

   [Crossref] [Google Scholar] [PubMed]

7. Saulescu I, Ionescu R, Opris-Belinski D. Interferon in systemic lupus erythematosus-A halfway between monogenic autoinflammatory and autoimmune disease. Heliyon. 2022;8(11):e11741.

   [Crossref] [Google Scholar] [PubMed]

8. Sim TM, Ong SJ, Mak A, Tay SH. Type I interferons in systemic lupus erythematosus: a journey from bench to bedside. Int J Mol Sci. 2022;23(5):2505.

   [Crossref] [Google Scholar] [PubMed]

9. Moltrasio C, Romagnuolo M, Marzano AV. NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: From cryopyrin function to targeted therapies. Front Immunol. 2022;13:1007705.

   [Crossref] [Google Scholar] [PubMed]

10. Blevins HM, Xu Y, Biby S, Zhang S. The NLRP3 Inflammasome pathway: A review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci. 2022;14:879021.

    [Crossref] [Google Scholar] [PubMed]